SCHEMBL5756499

SCHEMBL5756499

Cc1ccc(C(=O)N[C@@H](C)c2ccccc2)c(=O)n1-c1cccc(C#N)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.54
CNR2 P34972 3/20 0.54
NOTUM Q6P988 1/20 0.49
GPR139 Q6DWJ6 1/20 0.48
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
TSHR P16473 1/20 0.44
LIPG Q9Y5X9 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NAMPT P43490 1/20 0.43
POLB P06746 1/20 0.43
PTGER4 P35408 2/20 0.42
LMNA P02545 1/20 0.42
PHGDH O43175 1/20 0.42
PTGER1 P34995 2/20 0.42
PTGER2 P43116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759566 0.91 CNR2 (0.45) CNR1CNR2NOTUMGPR139LIPG
SCHEMBL5759245 0.91 PTGER4 (0.45) CNR1CNR2NOTUMGPR139KDM4E
SCHEMBL5756526 0.82 ELANE (0.57) CNR1CNR2NOTUMGPR139KDM4E
SCHEMBL5756492 0.82 ELANE (0.57) CNR1CNR2NOTUMGPR139KDM4E
SCHEMBL5930971 0.81 NOTUM (0.43) CNR1CNR2NOTUMKDM4EALDH1A1
SCHEMBL5757705 0.80 ELANE (0.55) CNR1CNR2NOTUMKDM4EALDH1A1
SCHEMBL5758147 0.77 HPGD (0.47) NOTUMKDM4EALDH1A1HPGDLMNA
SCHEMBL5757916 0.76 NOTUM (0.47) CNR2NOTUM
SCHEMBL5756911 0.76 ELANE (0.57) NOTUMKDM4EALDH1A1HPGDTSHR
SCHEMBL5755787 0.75 ELANE (0.46) NOTUMALDH1A1GAATOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 CNR1 2232/4885CNR2 2164/4885NOTUM 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.